The Confidence Game in Biotech | Ep. 972

Why a Successful Trial is Biotech's Most Dangerous Moment Welcome to the Bow Tied Biotech podcast, where science meets business. If breakthrough biotech, bold innovations, and the business behind the science gets you excited, you're in the right place. Make sure to check us out on Substack X and LinkedIn at at Bow Tied Biotech for even more insights and updates. All right, we've got a lot to cover today, so let's dive right in. Speaker 2 You know you usually expect a massive victory to just come with this, this sense of finality. Like the hero slays the dragon, the screen cuts to black, and you just assume the rest of the story is this quiet, predictable, happily ever after. Speaker 3 Yeah, we definitely crave that kind of clean resolution. Speaker 2 Right. But when you actually step into the world of biotechnology and drug development, that script gets completely flipped. So if you're putting your money into biotech or even just, you know, tracking these incredibly long development cycles, the most dangerous moment in a company's story is actually not when a make or break clinical trial fails. No, it's not. It's actually when that trial works. Speaker 3 Which is just a profoundly counterintuitive reality. I I mean for anyone looking at this industry totally, the standard assumption is always that passing a rigorous clinical trial just eliminates the existential threat to the company. Speaker 2 But based on the analytical transcript we're diving into today, the core mission of our discussion is really deconstructing how certainty is manufactured by these management teams. Speaker 3 Manufactured certainty. I like that, right? We're going to explore this framework that in the biotech industry, risk never actually disappears. It simply migrates to a completely different part of the business. Speaker 2 OK, so let's unpack this for everyone listening, because if you see a successful phase three trial and you immediately start calculating the future revenue, you are falling into what the sources call the the linear mental model. Speaker 3 Yeah, the linear. Speaker 2 Trap. Exactly. It's this incredibly seductive trap where we trick ourselves into evaluating biotech success as a simple checklist. Like, OK, you check the box for trial success, then you check the box for FDA approval. Speaker 3 Then the doctors prescribe it. Speaker 2 Right. You check that box and then you just sit back and wait for the cash flow. It feels entirely logical, but it completely misrepresents the actual mechanics of the industry. Speaker 3 It really does. I mean, that checklist mentality is deeply ingrained in how financial models are built. Wall Street loves a checklist, but biotech operates much more like a relay race. Speaker 2 A relay race. Speaker 3 Yeah, and the defining characteristic of a relay race is that every single handoff introduces a completely new mechanism for failure. You don't just clear a hurdle and leave it behind forever. Speaker 2 You have to pass the baton. Speaker 3 Exactly. You pass the baton to a different runner who has their own totally unique vulnerabilities. Speaker 2 It's like it's like treating the development cycle like a video game where you beat a boss and assume you never have to fight them again, but in reality it's like you drop your sword and have to run the next level completely barefoot. The whole mechanics of the game have just changed on you. Speaker 3 That is a perfect way to put it running barefoot. Speaker 2 So when a company clears that initial clinical risk when and they actually prove the science does what they claim it does, what specific hurdles are they picking up in its place? Speaker 3 Well, they immediately absorb this massive basket of invisible operational risks that simply didn't exist in the lab. The Hidden Durability and Operational Risks Post-Trial The text highlights durability risk, for instance. Speaker 2 OK. Durability risk, What does that look like? Speaker 3 So imagine a clinical trial shows just brilliant efficacy over a 12 week period. Everyone is thrilled, but chronic diseases require lifelong treatments. Yeah. You're not just taking it for three months. Yeah, exactly. So if the drug's efficacy wanes after, say, 18 months, the entire commercial model just collapses. And then then you introduce real world variability. Speaker 2 Oh, because trials are so controlled. Speaker 3 Incredibly controlled clinical trials are these pristine, heavily monitored environments. The patients are selected very carefully. They get constant reminders to take their doses. Their diets are meticulously tracked. Speaker 2 Right, but the real world is messy. I mean patients skip doses they take, contraindicating supplements they bought at the grocery store, they forget to show up for their follow up blood work. Speaker 3 All the time. Speaker 2 That pristine environment is just shattered the second the drug hits a normal pharmacy. Speaker 3 Which introduces severe operational constraints. I mean, a company might easily manage the logistics of administering some complex biologic to 500 trial participants at elite research hospitals. Speaker 2 Sure, you've got top Doctors watching them. Speaker 3 But scaling that exact same operational footprint to 50,000 patients across rural and suburban clinics, that introduces friction that the initial clinical checklist completely ignores. Speaker 2 But wait, let me push back on this a little bit. Isn't it management's fiduciary duty to highlight their wins? Like, if a management team passes a phase three trial, they absolutely should celebrate that milestone. It's a massive scientific achievement. Speaker 3 Oh. Speaker 2 Without a doubt. So it's not necessarily their fault if investors don't know how to read between the lines and anticipate all those logistical hurdles, right? Are these management teams just flat out lying to everyone to up their narrative? Speaker 3 No, no, they aren't lying. Management is absolutely doing their job by promoting the scientific win. The issue isn't deception, it's really the subtle art of compressing uncertainty into clean language. How Biotech Management Compresses Uncertainty with Language Compressing uncertainty, right? Speaker 3 Management teams are highly, highly skilled at making adjacent looming uncertainty feel completely irrelevant to the current moment. They utilize a very specific vocabulary to manage market perception and keep their cost of capital low. Speaker 2 The vocabulary of confidence. The sources break this down beautifully. You start hearing these highly polished corporate buzzwords just pumped out in press releases and earnings calls. Speaker 3 Yeah, you hear them everywhere. Speaker 2 Like a trial isn't just successful, the asset is now quote UN quote de risked. The data doesn't just look good, it is a registration enabling data package or they point to a clear regulatory pathway. Speaker 3 And The thing is, none of those phrases are technically false. The asset actually is technically de risk from a purely scientific standpoint, because the molecule does bind to the receptor as intended. Right? But the magic of that strategy is how it anchors the listeners attention entirely to the past victory rather than the future friction. Speaker 2 And here's where it gets really interesting for me. The text highlights one specific phrase as the absolute pinnacle of this strategy. And that phrase is commercially ready. Oh yes. Speaker 3 The big one. Speaker 2 The source explicitly notes that whenever a company claims they're commercially ready, that claims is inherently premature. Like almost always. Speaker 3 Because claiming to be commercially ready takes a literal mountain of future operational chaos. We're talking supply chain logistics, aggressive payer negotiations. Deploy an entire sales force. And it shrinks all of that down into two reassuring words. Speaker 2 2 words that make it sound like a done deal. Speaker 3 Exactly. It makes the remaining execution risk feel like this minor administrative task. Just paperwork. Speaker 2 So if the language is designed to obscure the remaining friction, we need to map out exactly where those risks are actually hiding once the science is proven, because we're moving from corporate PR to the hard reality of what the source calls risk substitution. From Safety to Labeling, Reimbursement, and Adoption Friction Risk substitution. Speaker 2 Yeah, it's basically a game of whack A mole. You smack down the efficacy risk, but before the press release even hits the wire, a completely different mole pops up on the other side of the board. Speaker 3 That's a great analogy. Speaker 2 So what do these new substituted risks actually look like when they hit the real world? Like what are the new moles? Speaker 3 Well, the source text lays out these undeniable handoffs where risk just mutates. Let's look at the transition from safety risk to labeling risk. For example, say a company shows a brilliantly clean safety profile in a small trial. The market cheers because the drug doesn't cause any severe immediate harm. But that safety profile has to survive the FDA review process, which looks at the data through a completely different lens. Speaker 2 Right, the FDA isn't just looking at the trial in a vacuum. Speaker 3 Exactly. The agency might agree the drug is safe, but only for a very specific, narrow subset of patients. Speaker 2 They might slap a black box warning on it, or they mandate that doctors can only prescribe it after a patient has already failed two other cheaper therapies. So you proved it was safe in the trial, but the FDA's labeling constraints just wiped out 80% of your total addressable market? Speaker 3 And that is the perfect illustration of risk substitution. The clinical risk is gone, but the commercial risk just exploded. And the next major hand off is the transition from approval risk to reimbursement risk. So let's say you navigate the FDA perfectly. You get a clean label. Speaker 2 Awesome. Pop the champagne again. Speaker 3 Right, the market assumes you've crossed the finish line. But the FDA's mandate is simply to determine if a drug is safe, effective. They do not care what it costs. Speaker 2 Right. The FDA saying yes, this works is in a completely different universe from an insurance payer or a pharmacy benefit manager saying yes, we are going to pay $100,000 a year for this. Speaker 3 Precisely. Payers operate on a roofless cost benefit analysis. If your newly approved drug is say 20% more effective than a generic that costs $4.00 a month, the payer will implement step therapy protocols. Speaker 2 What does that mean for the patient? Speaker 3 It means they build administrative walls to prevent doctors from prescribing the new drug until every other option is exhausted. The reimbursement risk can completely strangle A theoretically approved drug. Speaker 2 Which brings us to the final and maybe most frustrating handoff in the source material. Let's say you secure the reimbursement, the payers agree to cover it, the market is ecstatic. But then that product excitement slams face first into adoption friction at the actual clinic. Speaker 3 Yes, because physicians are human beings operating inside highly constrained, high pressure environments. They do not change their prescribing behavior simply because a new molecule is slightly superior. Speaker 2 Right, They have habits. They have workflows. Speaker 3 Exactly if a new treatment requires a four hour YV infusion, but a clinic's infusion chairs are tightly scheduled around one hour, chemotherapy drips. The doctor physically cannot prescribe your drug without destroying their practices daily workflow. Speaker 2 That's incredible. So the science works. The FDA approved it. The insurance will actually pay for it, but the logistical reality of the clinic's physical infrastructure prevents the patient from getting it. Speaker 3 The story gets exponentially more complex just in ways that are totally invisible to a standard financial model. Speaker 2 Which introduces this massive psychological disconnect for me. If these substituted risks are so complex and so dangerous to a company's survival, we really have to ask why the broader stock market consistently misprices them. Speaker 3 It's a great question. Why Investors Misprice Operational Risks and Inflate Narratives Because if everyone knows these operational risks exist, the fact that the stock price still spikes uncontrollably after a phase three trial means investors are actively choosing to ignore them. Why are we wired to systematically reward the science and discount the logistics? Speaker 3 It really comes down to how financial markets process and model different types of drama. Speaker 2 Drama. Speaker 3 Yeah, think about it. First order risks like a clinical trial failing are deeply dramatic and entirely binary. The data is either statistically significant or it isn't. The line on the chart goes up or it crashes to 0. Speaker 2 It's a huge event. Speaker 3 Right. An analyst can build a spreadsheet that assigns a clean mathematical percentage probability to that binary outcome. Speaker 2 Because it's quantifiable. You can't put physician stubbornness or an infusion chair bottlenecks into a discounted cash flow model. Speaker 3 Exactly the issue. 2nd order risks, reimbursement, negotiations, site of care constraints, real world adherence. They are slow, messy and fundamentally operational. Because you cannot easily model human friction, the market heavily discounts what it can only qualitatively understand. Speaker 2 That makes so much sense. Speaker 3 Investors gravitate toward the explosive binary risk because it offers a clear catalyst and they just put blinders on when it comes to the slow grinding operational reality. Speaker 2 But wait, this feels like almost a grand conspiracy. Are executives actively trying to trap investors with this? This cognitive dissonance creates the systemic pressure on management, right? Speaker 3 It's not a conspiracy, it's just the nature of the incentives. Management is heavily incentivized to navigate the narrative curve aggressively. The CEO has to transition the company's identity from a risky science project to a reliable commercial engine. Speaker 2 Because the market demands momentum. Speaker 3 Always. So they have to speak that commercial reality into existence long before the infrastructure is actually built. Speaker 2 The sources actually provide this fascinating decoder ring for how this narrative inflation plays out in real time. Like a management team doesn't just announce a successful phase three trial for a single asset, they translate that isolated win into quote proof of a platform. Speaker 3 Yes, the platform narrative. Speaker 2 Right. The implication is that because one drug worked, the company's entire underlying technological approach is infallible, which drastically inflates the perceived value of their early stage pipeline. Speaker 3 Or consider when they have a standard routine meeting with the FDA to discuss trial design. They don't just call it a meeting. The press release translates that interaction into alignment with regulatory agencies. It subtly implies this handshake deal that simply does not exist yet. Speaker 2 Even early launch preparations are weaponized. Hiring a handful of key account managers or regional sales directors is framed to investors as evidence of early demand. Speaker 3 Exactly. The entire narrative structure is engineered so that commercial dominance feels inevitable before the absolute hardest parts of the business model have ever been stress tested. Speaker 2 And because of these deeply entrenched incentives and our own psychological blind spots, this exact scenario plays out like a loop. We see the same predictable cycle over and over again in the market we do. A Playbook to Spot Narrative Expansion and Avoid Repricing So how does the cycle actually map out from the moment the science succeeds to the moment reality hits? Speaker 3 The source text outlines a very mechanical five step cycle. Speaker 2 OK, let's walk through it. Speaker 3 Step one. It begins. When an incredibly hard scientific problem appears to be solved, the pivotal trial hits its endpoints. Speaker 2 OK, check. Speaker 3 Step 2. Almost immediately the stock re rates, the valuation shoots up because the massive binary overhang has been removed from the financial models. Speaker 2 Right, that's the moment the market throws a parade and assumes the dragon is dead. Speaker 3 Exactly. Then step three, following that re rate, the narrative rapidly expands. Management starts talking about expanding the drug into larger patient populations, inflating the total addressable market. They announced new ambitious clinical programs. The company is basically priced for perfection. Speaker 2 But perfection isn't real, so Step 4. Speaker 3 Step 4, the constraints start to materialize. All those slow, messy operational realities we discussed, the push back from payers, the slow uptake from specialized clinics, the labeling restrictions, they begin to bleed into the quarterly earnings reports. Speaker 2 It starts showing up in the actual numbers. Speaker 3 Yes, And the final stage, Step 5, is the painful repricing the stock forcefully corrects as the broader market suddenly wakes up to the fact that commercializing a drug is fundamentally harder than inventing it. Speaker 2 So what does this all mean for you, the listener? How do you actually protect your thinking and spot that narrative expansion before Step 5 just crushes you? Speaker 3 The source material provides a highly actionable playbook to defend your analysis. First, whenever you encounter the word de risked in a corporate communication, you must immediately train yourself to ask what specific risk. Just replace the one that got removed. Speaker 2 Don't accept the vacuum. Speaker 3 Exactly. Find the new substituted risk. Speaker 2 Look for the handoff. Speaker 3 Second, you need to shift your analytical focus away from the isolated molecule and rigorously examine the system surrounding it. Ask the mundane operational questions. Who physically administers this drug? Is the administration process scalable in a normal, understaffed suburban clinic? Will the pharmacy benefit manager force patients to fail on an older drug first? Speaker 2 So you have to look past the brilliance of the science and interrogate the friction of the logistics. Speaker 3 Precisely. Yeah. And finally, you must elevate your skepticism exactly when the story feels the cleanest. Speaker 2 Wait, really? When it feels the cleanest. Speaker 3 Yes, because if a narrative in the biotech space has no visible friction, that is a massive red flag. That moment of perfect clarity is historically when the market is the most detached from reality. You have to internalize the core premise of the text. The remaining risks aren't just hurdles to clear. The remaining risks are the business. Speaker 2 The remaining risks are the business Wow, that completely reframes how you look at a press release. So to pull all these threads together for you listening, the biotech game isn't a story about eliminating uncertainty. They are entirely in the business of transferring it. Absolutely. They transfer from the clinical lab to the operational supply chain, from proving scientific efficacy to battling behavioral inertia in doctors. And the market is consistently at its most vulnerable right after it thinks it is definitively 1. The Future Where Logistics Define Biotech Company Value And, you know, we can take this concept of risk substitution and push it even further into an area the sources barely hint at. But it's fascinating to think about. Well, if the biggest turtles to saving lives are ultimately reimbursement roadblocks, physician adoption, friction, and sight of care constraints, what happens when the science actually gets easy? Speaker 2 Easy, yeah. Speaker 3 Like if artificial intelligence eventually reaches a point where it can perfectly model protein folding and predict clinical efficacy with near total certainty, the scientific risk basically drops to 0 the. Speaker 2 Ultimate de risking. Speaker 3 Exactly the point. If AI solves the molecule discovery problem completely, do biotech companies stop being science companies companies altogether? Does the entire industry essentially turn into a logistics and distribution apparatus? Because if a computational model can invent a miracle drug in an afternoon, but it still takes five years to convince a fragmented healthcare system to actually pay for it and administer it, the true innovation isn't the biology anymore. The only innovation that matters is the operational machinery required to get a slow, stubborn system to use it. Speaker 2 Because if a miracle drug works perfectly, but the system refuses to administer it, did the science actually matter? If the science becomes a commodity, the logistics become the entire value of the company. That completely shatters the illusion of the lone genius in the lab coat. Speaker 3 It really does. Speaker 2 The dragon might be dead on the floor, but if you can't figure out the logistics of getting the gold out of The Cave, the victory doesn't actually matter. Well, thank you for joining us on The Steep Dive. Keep questioning those clean narratives, look for the substituted risks, and we will be back to unpack more realities with you next time. Speaker 1 You have been listening to the Bow Tied Biotech podcast. Make sure to check us out on Substack X and LinkedIn at at Bow Tied Biotech for even more insights and updates. We appreciate your support and see you next week.